Arax Advisory Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$110K Buy
+347
New +$81.8K ﹤0.01% 2664
2026
Q1
Sell
-50
Closed -$9.45K 4104
2025
Q4
$9.45K Sell
50
-16
-24% -$3.07K ﹤0.01% 2497
2025
Q3
$11.7K Buy
+66
New +$9.81K ﹤0.01% 2523
2025
Q2
Sell
-13
Closed -$1.37K 3137
2025
Q1
$1.37K Sell
13
-30
-70% -$3.39K ﹤0.01% 2204
2024
Q4
$4.61K Hold
43
﹤0.01% 1768
2024
Q3
$4.3K Hold
43
﹤0.01% 1779
2024
Q2
$3.62K Buy
+43
New +$3.42K ﹤0.01% 1727

Other funds holding LGND

Arax Advisory Partners's LGND Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 347 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2664 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in LGND as recently as Q4 2025.

Arax Advisory Partners first reported a position in LGND in Q2 2024 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Arax Advisory Partners held 347 shares of Ligand Pharmaceuticals worth $110K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2664 holding.
  • Arax Advisory Partners first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.